D3

D3 (PENTA 21): A randomised non-inferiority trial with nested PK to assess DTG/3TC fixed dose formulations for the maintenance of virological suppression in children with HIV infection aged 2 to <15 years old

 

HIV infection implies taking medicines for life. Therefore, it is important that they not only work well, but also that they continue to be safe, with a low chance of long-term side effects, and that they are easy to take every day. Anti-HIV treatment using two medicines instead of three may be one way of achieving this.

This study aims to find out whether treating children and young people living with HIV with two anti‑HIV medicines, dolutegravir (DTG) and lamivudine (3TC), is safe and as effective as the three-medicine anti-HIV treatments currently used in routine practice.


This Penta-sponsored study is carried out in close collaboration with the MRC CTU leading the operations activities and with active participation of PHPT CTU (Thailand). The study is planned to start in July 2021 and will include 370 children and young people from Uganda, South Africa, Thailand, UK and Spain. The study is funded by ViiV Healthcare.

 

NEWSLETTER

We would like to update you on our recent activities